Illumina (NASDAQ:ILMN) Price Target Lowered to $150.00 at Guggenheim

Illumina (NASDAQ:ILMN) had its price target trimmed by Guggenheim from $170.00 to $150.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on the life sciences company’s stock.

ILMN has been the topic of several other research reports. Leerink Partners increased their price objective on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Morgan Stanley decreased their price objective on Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Stephens increased their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Finally, Royal Bank of Canada raised their price target on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Nine investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $161.40.

Illumina Stock Down 9.6 %

Shares of NASDAQ ILMN opened at $111.06 on Friday. Illumina has a 1 year low of $100.08 and a 1 year high of $156.66. The firm has a 50-day simple moving average of $136.70 and a two-hundred day simple moving average of $135.29. The company has a market cap of $17.61 billion, a P/E ratio of -14.46 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Research analysts anticipate that Illumina will post 4.42 earnings per share for the current year.

Institutional Trading of Illumina

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc boosted its holdings in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new stake in shares of Illumina in the fourth quarter worth approximately $32,000. Assetmark Inc. increased its position in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina during the fourth quarter worth approximately $45,000. Finally, TD Private Client Wealth LLC raised its stake in Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.